Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.
Explore this paper's citation graph
Summary
Level 1 evidence exists to support the use of nivolumab as second-line treatment of patients with squamous advanced NSCLC, as well as in select patients with nonsquamous disease.
- Type
- article
- Published
- 2016-09-27
- Cited by
- 82
- References
- 48
- OpenAlex
- https://openalex.org/W26884577
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:43806331
Keywords
Humanities, Political science, Philosophy
References
- Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.
- Maintenance therapy in non-small cell lung cancer
- Abstract CT104: Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001)
- Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
- Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer
- Pembrolizumab for the treatment of non-small-cell lung cancer.
- Maintenance treatment with different strategies in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
- PD-1: an inhibitory immunoreceptor involved in peripheral tolerance.
- New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Positive and Negative Regulation of Cellular Immune Responses in Physiologic Conditions and Diseases
- The blockade of immune checkpoints in cancer immunotherapy
- Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
- Enhancement of Antitumor Immunity by CTLA-4 Blockade
- Immune Checkpoint Blockade in Cancer Therapy.
- Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
- PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Cited by
- PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
- Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
- Shooting for the Moon or Flying Too Near the Sun? Crossing the Value Rubicon in Precision Cancer Care
- A Cost‐Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD‐L1 Testing
- DNA Repair Gene Polymorphisms in Non-Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Containing Chemotherapy
- Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report.
- Exhaled Breath Analysis for Lung Cancer
- Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment
- OMIP‐037: 16‐color panel to measure inhibitory receptor signatures from multiple human immune cell subsets
- Immunotherapy for Lung Cancer: No Longer an Abstract Concept
- Stage III Non-small Cell Lung Cancer
- Inducible expression of cancer-testis antigens in human prostate cancer
- Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment
- Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer.
- EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
- Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
- Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis
- Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer
- Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
- New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib
Related papers
No related papers recorded.